Priscilla K Brastianos

May 30, 2024 | medscape.com | Fatima Cardoso |Priscilla K Brastianos |Laura A. Huppert |Orit Kaidar-Person

Authors and Disclosures Fatima Cardoso, MD Director, Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal Disclosure: Fatima Cardoso, MD, has disclosed the following relevant financial relationships: Personal financial interest in form of consultancy role for: Amgen; Astellas/Medivation; AstraZeneca; Celgene; Daiichi-Sankyo; Eisai; GE Oncology; Genentech; Gilead; GlaxoSmithKline; IQVIA; Macrogenics; Medscape; Merck-Sharp; Merus BV; Mylan; Mundipharma; Novartis; Pfizer; Pierre-Fabre;...

May 17, 2024 | acsjournals.onlinelibrary.wiley.com | Annie L. Hsieh |Wenya Linda Bi |Vijaya Ramesh |Priscilla K Brastianos

Priscilla K.

Feb 1, 2024 | thejns.org | Hugues Duffau |Mitchel Berger |Priscilla K Brastianos |Nader Sanai

Correspondence Hugues Duffau: [email protected]. INCLUDE WHEN CITING DOI: 10.3171/2023.11.FOCUS23731.

Oct 26, 2023 | healio.com | Drew Amorosi |Mindy Valcarcel |Priscilla K Brastianos |Carey Anders

You've successfully added Hematology Oncology: Breast Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. An estimated 10% to 40% of patients with solid tumors develop brain metastases.

Aug 1, 2023 | thejns.org | Manish K. Aghi |Priscilla K Brastianos |Albert Kim |Steven Kalkanis

INTRODUCTIONBrain metastases (BMs), the most common adult intracranial tumor,1 confer a worse prognosis than cancers lacking BMs.2 In this issue of Neurosurgical Focus, we integrate information on advancements in BM management, research that will drive future treatments, and a roadmap for future research.